Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

MedWellAI (MWAI) EBITDA Margin (2017 - 2026)

MedWellAI has reported EBITDA Margin over the past 9 years, most recently at 48.41% for Q4 2025.

  • Quarterly EBITDA Margin rose 16484.0% to 48.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 32.02% through Dec 2025, down 10951.0% year-over-year, with the annual reading at 128.07% for FY2025, N/A changed from the prior year.
  • EBITDA Margin was 48.41% for Q4 2025 at MedWellAI, up from 330.64% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1331.92% in Q2 2021 and troughed at 51062.02% in Q3 2024.
  • The 5-year median for EBITDA Margin is 66.89% (2022), against an average of 2679.31%.
  • Year-over-year, EBITDA Margin crashed -5020685bps in 2024 and then skyrocketed 5073138bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 13.03% in 2021, then crashed by -1166bps to 164.91% in 2022, then skyrocketed by 88bps to 19.42% in 2023, then crashed by -998bps to 213.25% in 2024, then skyrocketed by 77bps to 48.41% in 2025.
  • Per Business Quant, the three most recent readings for MWAI's EBITDA Margin are 48.41% (Q4 2025), 330.64% (Q3 2025), and 612.1% (Q2 2025).